BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND TERT, EST2, Q8NG46, Q8N6C3, Q2XS35, O14783, O14746, 7015, hEST2, TCS1, TRT, TP2 AND Treatment
237 results:

  • 1. Trauma plays an important role in acral melanoma: A retrospective study of 303 patients.
    Huang R; Zhao M; Zhang G; Yang Y; Wang J; Zheng K; Li L; Su X; Zhao L; Wu Y; Zou Z
    Cancer Med; 2024 Apr; 13(7):e7137. PubMed ID: 38545846
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Predicting the prognosis of glioma patients with tert promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy.
    Cao W; Lan J; Hu C; Kong J; Xiang L; Zhang Z; Sun Y; Zeng Z; Lei S
    Aging (Albany NY); 2024 Mar; 16(6):5618-5633. PubMed ID: 38499392
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.
    Keric N; Krenzlin H; Kalasauskas D; Freyschlag CF; Schnell O; Misch M; von der Brelie C; Gempt J; Krigers A; Wagner A; Lange F; Mielke D; Sommer C; Brockmann MA; Meyer B; Rohde V; Vajkoczy P; Beck J; Thomé C; Ringel F
    J Neurooncol; 2024 Mar; 167(1):133-144. PubMed ID: 38326661
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. tert promoter mutations in atypical melanocytic lesions: A series of seven cases with adverse melanoma-specific outcome.
    Huber R; Lee J; Borretta L; Tessier-Cloutier B; Lum A; Yip S; Horst BA
    Hum Pathol; 2024 Feb; 144():34-39. PubMed ID: 38224873
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Prognostic and predictive biomarkers in paediatric solid tumours.
    Glembocki AI; Somers GR
    Pathology; 2024 Mar; 56(2):283-296. PubMed ID: 38216399
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. The Biological and Clinical Role of the Telomerase Reverse Transcriptase Gene in Glioblastoma: A Potential Therapeutic Target?
    Di Nunno V; Aprile M; Bartolini S; Gatto L; Tosoni A; Ranieri L; De Biase D; Asioli S; Franceschi E
    Cells; 2023 Dec; 13(1):. PubMed ID: 38201248
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. "De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade.
    Hadad S; Gupta R; Oberheim Bush NA; Taylor JW; Villanueva-Meyer JE; Young JS; Wu J; Ravindranathan A; Zhang Y; Warrier G; McCoy L; Shai A; Pekmezci M; Perry A; Bollen AW; Phillips JJ; Braunstein SE; Raleigh DR; Theodosopoulos P; Aghi MK; Chang EF; Hervey-Jumper SL; Costello JF; de Groot J; Butowski NA; Clarke JL; Chang SM; Berger MS; Molinaro AM; Solomon DA
    Acta Neuropathol; 2023 Dec; 147(1):3. PubMed ID: 38079020
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Primary mucosal melanomas of the urogenital tract: a clinical, pathological, and genetic nationwide survey of Danish patients 1990-2019.
    Znaider VK; Mikkelsen LH; Jensen CFS; Sønksen J; Heegaard S
    Scand J Urol; 2023 Aug; 58():52-59. PubMed ID: 37635444
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Vanadium(V) Pyridine-Containing Schiff Base Catecholate Complexes are Lipophilic, Redox-Active and Selectively Cytotoxic in Glioblastoma (T98G) cells.
    Kostenkova K; Levina A; Walters DA; Murakami HA; Lay PA; Crans DC
    Chemistry; 2023 Dec; 29(68):e202302271. PubMed ID: 37581946
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Differences in clinical outcomes based on molecular markers in glioblastoma patients treated with concurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trial.
    Cappelli L; Khan MM; Kayne A; Poiset S; Miller R; Ali A; Niazi M; Shi W; Alnahhas I
    Chin Clin Oncol; 2023 Jun; 12(3):23. PubMed ID: 37417289
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Activity and Selectivity of Novel Chemical Metallic Complexes with Potential Anticancer Effects on Melanoma cells.
    Ciardulli MC; Mariconda A; Sirignano M; Lamparelli EP; Longo R; Scala P; D'Auria R; Santoro A; Guadagno L; Della Porta G; Longo P
    Molecules; 2023 Jun; 28(12):. PubMed ID: 37375406
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel.
    Kisistók J; Christensen DS; Rasmussen MH; Duval L; Aggerholm-Pedersen N; Luczak AA; Sorensen BS; Jakobsen MR; Oellegaard TH; Birkbak NJ
    Melanoma Res; 2023 Oct; 33(5):364-374. PubMed ID: 37294123
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With Glioma.
    Benusiglio PR; Elder F; Touat M; Perrier A; Sanson M; Colas C; Guerrini-Rousseau L; Tran DT; Trabelsi N; Carpentier C; Marie Y; Adam C; Bernier M; Cazals-Hatem D; Mokhtari K; Tran S; Mathon B; Capelle L; Dhooge M; Idbaih A; Alentorn A; Houillier C; Dehais C; Hoang-Xuan K; Cuzzubbo S; Carpentier A; Duval A; Coulet F; Bielle F
    JCO Precis Oncol; 2023 May; 7():e2200525. PubMed ID: 37262394
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Prognostic role and interaction of tert promoter status, telomere length and MGMT promoter methylation in newly diagnosed IDH wild-type glioblastoma patients.
    Giunco S; Padovan M; Angelini C; Cavallin F; Cerretti G; Morello M; Caccese M; Rizzo B; d'Avella D; Puppa AD; Chioffi F; De Bonis P; Zagonel V; De Rossi A; Lombardi G
    ESMO Open; 2023 Jun; 8(3):101570. PubMed ID: 37230028
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Effect of 12-months testosterone replacement therapy on bone mineral density and markers of bone turnover in testicular cancer survivors - results from a randomized double-blind trial.
    Jørgensen PL; Kreiberg M; Jørgensen N; Juul A; Oturai PS; Dehlendorff C; Lauritsen J; Wagner T; Rosenvilde J; Daugaard G; Medici CR; Jørgensen NR; Bandak M
    Acta Oncol; 2023 Jul; 62(7):689-695. PubMed ID: 37151105
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Targeted α-Therapy Using
    Ertveldt T; Krasniqi A; Ceuppens H; Puttemans J; Dekempeneer Y; Jonghe K; Mey W; Lecocq Q; Vlaeminck Y; Awad RM; Goyvaerts C; Veirman K; Morgenstern A; Bruchertseifer F; Keyaerts M; Devoogdt N; D'Huyvetter M; Breckpot K
    J Nucl Med; 2023 May; 64(5):751-758. PubMed ID: 37055223
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. tert Immunohistochemistry as a Surrogate Marker for tert Promoter Mutations in Infiltrating Gliomas.
    Dono A; Moosvi AM; Goli PS; Bellman AC; Aung PP; Esquenazi Y; Ballester LY
    Appl Immunohistochem Mol Morphol; 2023 May-Jun 01; 31(5):288-294. PubMed ID: 36952585
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Deep Learning Radiomics for the Assessment of Telomerase Reverse Transcriptase Promoter Mutation Status in Patients With Glioblastoma Using Multiparametric MRI.
    Zhang H; Zhang H; Zhang Y; Zhou B; Wu L; Lei Y; Huang B
    J Magn Reson Imaging; 2023 Nov; 58(5):1441-1451. PubMed ID: 36896953
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Clinical, histological, and molecular features of gliomas in adults with neurofibromatosis type 1.
    Romo CG; Piotrowski AF; Campian JL; Diarte J; Rodriguez FJ; Bale TA; Dahiya S; Gutmann DH; Lucas CG; Prichett L; Mellinghoff I; Blakeley JO
    Neuro Oncol; 2023 Aug; 25(8):1474-1486. PubMed ID: 36840626
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Combined analysis of PHOX2B at two time points and its value for further risk stratification in high-risk neuroblastoma.
    Yue Z; Gao C; Xing T; Zhao W; Duan C; Wang X; Jin M; Su Y
    Pediatr Blood Cancer; 2023 May; 70(5):e30261. PubMed ID: 36815592
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 12.